RC
MTNB icon

RegentAtlantic Capital’s Matinas BioPharma MTNB Stock Holding History

RegentAtlantic Capital’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-300
Closed -$16K – 638
2021
Q1 		$16K Sell
300
-100
-25% -$6.71K ﹤0.01% 547
2020
Q4 		$27K Hold
400
– – ﹤0.01% 498
2020
Q3 		$15K Hold
400
– – ﹤0.01% 490
2020
Q2 		$15K Hold
400
– – ﹤0.01% 474
2020
Q1 		$12K Hold
400
– – ﹤0.01% 413
2019
Q4 		$45K Buy
+400
New +$23.2K ﹤0.01% 459

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

RegentAtlantic Capital's MTNB Position: Q2 2021 in Review

RegentAtlantic Capital sold out of Matinas BioPharma (MTNB) in Q2 2021, closing a stake of 300 shares — an estimated $16K sold.

RegentAtlantic Capital first reported a position in MTNB in Q4 2019 and held it in 6 quarters. The position peaked at $45K in Q4 2019. 67 funds tracked by Wall St. Rank hold MTNB as of Q2 2021.

  • RegentAtlantic Capital reported no remaining Matinas BioPharma position as of Q2 2021 after selling out during the quarter.
  • RegentAtlantic Capital sold 300 Matinas BioPharma shares in Q2 2021, an estimated $16K.
  • RegentAtlantic Capital first reported a position in Matinas BioPharma in Q4 2019 and held it in 6 quarters.
  • RegentAtlantic Capital's Matinas BioPharma position peaked at $45K in Q4 2019.
  • 67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2021.

Based on RegentAtlantic Capital's 13F filing for Q2 2021, filed 12 Aug 2021.